GHB: EFFECTS, WITHDRAWAL, AND TREATMENT

GHB：影响、戒断和治疗

• 批准号: 7606766
• 负责人: KAREN A MIOTTO
• 金额: $ 0.03万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-02-21 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7606766
• 关键词: Agitation; Alcohol withdrawal syndrome; Anxiety; Attenuated; Benzodiazepines; Blood Pressure; Butylene Glycols; Computer Retrieval of Information on Scientific Projects Database; Confusion; Country; Delirium; Diazepam; Drug Metabolic Detoxication; Evidence based treatment; Funding; Goals; Grant; Guidelines; Hallucinations; Heart Rate; Hour; Institution; Lorazepam; Nausea; Participant; Patients; Pharmaceutical Preparations; Phase; Purpose; Research; Research Personnel; Resources; Safety; Severities; Signs and Symptoms; Sleeplessness; Source; Substance Withdrawal Syndrome; Sweat; Sweating; Symptoms; Tremor; United States National Institutes of Health; Withdrawal; Withdrawal Symptom; drug of abuse; gamma hydroxybutyrate; prevent; treatment center

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Gamma-hydroxybutyrate (GHB) and GHB precursors such as 1,4-butanediol, gamma-butryolactone (GBL) are emerging drugs of abuse used across the country. Unfortunately many treatment centers are not familiar with this drug or the signs and symptoms of withdrawal from GHB or its precursors. Dependent users develop a withdrawal syndrome similar to alcohol withdrawal. Withdrawal symptoms typically begin one to six hours after last use. Early symptoms include anxiety, tremor, insomnia, and nausea; as well as sweating, elevated heart rate and blood pressure. In cases of severe withdrawal, delirium can occur including confusion, hallucinations and agitation. There are no evidence-based treatment guidelines for the treatment of GHB withdrawal. However, patients presenting for treatment generally are treated with a benzodiazepine. The purpose of these studies are to quantify the signs and symptoms of GHB withdrawal, identify predictors of withdrawal severity and evaluate the safety and feasibility of drug treatment for GHB detoxification. The study involves three phases. In the first phase of the study participants will be given lorazepam for the treatment of "mild" GHB withdrawal. Lorazepam is a benzodiazepine similar to Valium. All participants will be treated with the goal of attenuating symptoms and preventing withdrawal progression. However, some participants will progress into "moderate" or "severe" withdrawal.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 中心，不一定是研究者的机构。 γ-羟基丁酸酯 (GHB) 和 GHB 前体，如 1,4-丁二醇、γ-丁内酯 (GBL) 是全国各地使用的新兴滥用药物。 不幸的是，许多治疗中心不熟悉这种药物或 GHB 或其前体戒断症状和体征。 依赖性使用者会出现类似于酒精戒断的戒断综合症。戒断症状通常在最后一次使用后一到六个小时开始出现。 早期症状包括焦虑、震颤、失眠和恶心；以及出汗、心率和血压升高。 在严重戒断的情况下，可能会出现谵妄，包括精神错乱、幻觉和烦躁。目前尚无针对 GHB 戒断治疗的循证治疗指南。 然而，就诊的患者通常接受苯二氮卓类药物治疗。这些研究的目的是量化 GHB 戒断症状和体征，确定戒断严重程度的预测因素，并评估 GHB 解毒药物治疗的安全性和可行性。该研究分为三个阶段。 在研究的第一阶段，参与者将接受劳拉西泮治疗“轻度”GHB 戒断。 劳拉西泮是一种类似于安定的苯二氮卓类药物。所有参与者都将接受治疗，目标是减轻症状并防止戒断进展。 然而，一些参与者会进展为“中度”或“严重”戒断。